ClinicalTrials.gg
CompletedNCT05652660Updated Jul 26, 2024Results posted

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

A Phase 1 interventional study of ARV-471 and Rosuvastatin in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to understand if ARV-471 affects how a BCRP substrate (rosuvastatin) gets into the body in healthy adults.

All participants in this study will receive one dose of rosuvastatin alone by mouth in Period 1. In Period 2, everyone will receive one dose of ARV-471 by mouth 90 min before one dose of rosuvastatin by mouth. The levels of rosuvastatin in Period 1 will be compared to the levels of rosuvastatin in Period 2 to determine if ARV-471 affects how rosuvastatin gets into the body differently in healthy adults.

All participants will stay at the study clinic for 10 days and 9 nights.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female participants of non- must be 18 to 65 years of age, inclusive at the time of signing document.
  • Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical exam, laboratory tests, vital sign and standard 12-lead ECGs.
  • of 17.5 to 32 kg/m2; and a total body weight ≥45 kg.

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Pregnant female participants; breastfeeding female participants; Male participants with partners currently pregnant; fertile male participants who have partners of and are unwilling or unable to use a highly effective method of as outlined in this protocol for the duration of the study and for 90 days after the last dose of product.
  • Participants with known history of to statin medication, sensitivity to ARV-471 or rosuvastatin or any of the formulation components of ARV-471 or rosuvastatin.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  • A positive urine drug test.
  • History of use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Rosuvastatin with/without ARV-471

    Rosuvastatin administered as a single dose in Period 1 and Period 2. ARV-471 administered as a single dose in Period 2.

    Drug: ARV-471 · Drug: Rosuvastatin

Interventions

  • Experimental

    Also known as: PF-07850327

  • Probe substrate

    Also known as: CRESTOR®

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Rosuvastatin

    Cmax was defined as maximum plasma concentration. Cmax of rosuvastatin was observed directly from data.

    Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours post dose on Day 1 in Periods 1 and 2

  2. Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Rosuvastatin

    AUClast was defined as area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast of rosuvastatin was determined using Linear/Log trapezoidal method.

    Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours post dose on Day 1 in Periods 1 and 2

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

    Time frame: From the first dose (Day 1) up to 35 days after the last dose (Day 6) of study intervention (up to 41 days)

  2. Number of Participants With Clinical Laboratory Abnormalities (Without Regard to Baseline Abnormality)

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid, cystatinC); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (dipstick \[decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, bilirubin\], microscopy. Abnormality was determined at the investigator's discretion.

    Time frame: Baseline (Period 1 Day -1) up to Period 2 Day 4 (10 days)

  3. Number of Participants With Electrocardiogram (ECG) Abnormalities

    ECG abnormalities criteria include a) a postdose QTc corrected using Fridericia's formula (QTcF) increased by \>60 millisecond (ms) from the baseline and the absolute QTcF value \>450 ms; or b) an absolute QTcF value \>500 ms for any scheduled ECG.

    Time frame: Baseline (Period 1 Day 1) up to Period 2 Day 4 (9 days)

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs (blood pressure and pulse rate) were obtained with participant following at least a 5-minute rest in a supine position. Clinical significance of vital signs was determined at the investigator's discretion.

    Time frame: Baseline (Period 1 Day 1) up to Period 2 Day 4 (9 days)

07

Results

Posted Jul 26, 2024

Participant flow

Period 1 (5 Days)
Participant flow — Period 1 (5 Days)
MilestoneAll Participants
Started12
Treated12
Completed12
Not completed0
Period 2 (4 Days)
Participant flow — Period 2 (4 Days)
MilestoneAll Participants
Started12
Treated12
Completed12
Not completed0

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Rosuvastatin

Cmax was defined as maximum plasma concentration. Cmax of rosuvastatin was observed directly from data.

Time frame:
0 (predose), 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours post dose on Day 1 in Periods 1 and 2
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Rosuvastatin
nanogram per milliliter (ng/mL)Period 1: RosuvastatinPeriod 2: ARV-471 + Rosuvastatin
Maximum Plasma Concentration (Cmax) of Rosuvastatin2.178 ± 532.625 ± 48
Statistical analysis
  • Period 1: Rosuvastatin vs Period 2: ARV-471 + Rosuvastatin · Ratio (%) of adjusted geometric means: 120.50 · 90% CI 104.77 to 138.59The ratios (and 90% CIs) are expressed as percentages.
PrimaryArea Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Rosuvastatin

AUClast was defined as area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast of rosuvastatin was determined using Linear/Log trapezoidal method.

Time frame:
0 (predose), 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 hours post dose on Day 1 in Periods 1 and 2
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Rosuvastatin
nanogram*hour per milliliter (ng*hr/mL)Period 1: RosuvastatinPeriod 2: ARV-471 + Rosuvastatin
Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Rosuvastatin31.40 ± 4034.71 ± 40
Statistical analysis
  • Period 1: Rosuvastatin vs Period 2: ARV-471 + Rosuvastatin · Ratio (%) of adjusted geometric means: 110.56 · 90% CI 103.53 to 118.06The ratios (and 90% CIs) are expressed as percentages.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

Time frame:
From the first dose (Day 1) up to 35 days after the last dose (Day 6) of study intervention (up to 41 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPeriod 1: RosuvastatinPeriod 2: ARV-471 + Rosuvastatin
Treatment-emergent AEs13
Treatment-emergent SAEs00
SecondaryNumber of Participants With Clinical Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid, cystatinC); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (dipstick \[decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, bilirubin\], microscopy. Abnormality was determined at the investigator's discretion.

Time frame:
Baseline (Period 1 Day -1) up to Period 2 Day 4 (10 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsPeriod 1: RosuvastatinPeriod 2: ARV-471 + Rosuvastatin
Number of Participants With Clinical Laboratory Abnormalities (Without Regard to Baseline Abnormality)24
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

ECG abnormalities criteria include a) a postdose QTc corrected using Fridericia's formula (QTcF) increased by \>60 millisecond (ms) from the baseline and the absolute QTcF value \>450 ms; or b) an absolute QTcF value \>500 ms for any scheduled ECG.

Time frame:
Baseline (Period 1 Day 1) up to Period 2 Day 4 (9 days)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsPeriod 1: RosuvastatinPeriod 2: ARV-471 + Rosuvastatin
Number of Participants With Electrocardiogram (ECG) Abnormalities00
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs (blood pressure and pulse rate) were obtained with participant following at least a 5-minute rest in a supine position. Clinical significance of vital signs was determined at the investigator's discretion.

Time frame:
Baseline (Period 1 Day 1) up to Period 2 Day 4 (9 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsPeriod 1: RosuvastatinPeriod 2: ARV-471 + Rosuvastatin
Number of Participants With Clinically Significant Change From Baseline in Vital Signs00

Adverse events

Collected over From the first dose (Day 1) up to 35 days after the last dose (Day 6) of study intervention (up to 41 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Rosuvastatin0/12 (0%)0/12 (0%)1/12 (8.3%)
Period 2: ARV-471 + Rosuvastatin0/12 (0%)0/12 (0%)3/12 (25%)
Most frequent other events
Most frequent other events
EventPeriod 1: RosuvastatinPeriod 2: ARV-471 + Rosuvastatin
Abdominal painGastrointestinal disorders1/120/12
Muscle spasmsMusculoskeletal and connective tissue disorders0/121/12
DizzinessNervous system disorders0/121/12
HeadacheNervous system disorders0/121/12

Baseline characteristics

The baseline analysis population defined as all participants enrolled and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)All Participants
Mean50.5 ± 9.16
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female3
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino4
Not Hispanic or Latino8
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White8
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Feb 2023, 2 months.

Results were first posted in Jul 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Dec 15, 2022
StartActual
Dec 9, 2022
Primary completionActual
Feb 9, 2023
CompletionActual
Mar 6, 2023
Results first posted
Jul 26, 2024
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05652660
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc.
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
Dec 9, 2022
Primary completion
Feb 9, 2023
Completion
Mar 6, 2023
Results posted
Jul 26, 2024
Last update
Jul 26, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepdegestrant

Start the discussion